<i>6</i> 2					_						
国	Substitute for form 1449A/PTO						Complete if Known				
[5]	温 INFORMATION DISCLOSU					-	Application Number 10/685,				
🔰	STATEMENT BY APPLICANT								r 14, 2003		
& HADENARIA	(Use several sheets if nece				ssarv)		First Name Inventor Ding,		et al.		
She						1	Attorney Docket Number 20861		US3		
			<u> </u>		U.S. PA	TE	NT DOCUMENTS	·			
			U.S. Patent Document								
Examiner Initials'		Cite No.'	Kind Co			de²	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document		
1111111	ais	140.	Number (if know					MM-DD-YYYY			
		A									
						PA	TENT DOCUMENTS				
<u></u>		0.4	Foreign Patent Document			Name of Days and a second		Date of	T		
Examiner Initials'		Cite No.'	Office Number Kind			Name of Patentee or Applicant of Cited Document			Publication of Cited Document		
	1			·	Code ⁵ (if known)				MM-DD-YYYY		
TA	M	B1	WO99/21845			A٤	Agouron Pharmaceuticals Inc.		05/06/1999		
	1	B2	WO00/75120			Agouron Pharmaceuticals Inc.			12/14/2000		
		B3 WO97/1		//16447	16447		itotix Inc.	05/09/1997			
	B4		WO99/43675			Hoechst Marion Roussel Inc.			09/02/1999		
		B5	WO99/43676			Hoechst Marion Roussel Inc.		09/02/1999			
		B6 WO98/33798		W	Warner Lambert Co.		08/06/1998				
		B 7	37 WO99/09030			W	arner Lambert Co.	02/25/1999			
		B8	B8 WO00/39101			Astrazeneca Ltd.			07/06/2000		
		B9	WO00/12485			Zeneca Ltd.			03/09/2000		
		B10	WO99/24416			Bristol-Myers Squibb Co.		03/09/1999			
		B11	WO99/21845			Agouron Pharmaceuticals Inc.		05/06/1999			
		B12	WO 00/26202			Ph	Pharmacia & UpJohn S.P.A.		05/11/2000		
			WO 01/56567			No	Novo Nordisk A/S		08/09/2001		
		B14	WO 0	1/60816		Ar	ngen Inc.		08/23/2001		
	/	B15	WO 0	1/79198		Αę	gouron Pharmaceuticals	s, Inc.	12/25/2001		
(A)	~/	B16	WO 02	2/12250		Αg	gouron Pharmaceuticals	s, Inc.	02/14/2002		
	_			NON	PATENT	ı.it	ERATURE DOCUMENT	`S			
NON PATENT LITERATURE DOCUMENTS NON PATENT LITERATURE DOCUMENTS Non Patent Literature Documents C1 Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vo.									92 pgs. 376-	\vdash	
100	1		387								
	C2 Chong, Wesley, K. M., Presentation at Gordon Confere							onference	ce on		
			Medicinal Chemistry, Colby Sawyer College, New London, NH								
	l		"Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August								
	١.		2, 1999 (Copy of Conference Handout Enclosed)								
C3 Fischer et al., Expert Opin. Investig. Drugs 12(6) pgs. 955-970 (5-970 (2003)			
M	74	C4					ance Vol. 6, pgs. 15-26 (2003)				
12	•	· · · ·									

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

Examiner

Signature

Date Considered

To Administration to applicant, include considered, meaner or not citation is in conformance with mercer dos. Disw line through citation it not no conformance and not considered. Include copy of the form with next communication to applicant.

*Unique citation designation number. See attached Kinds of U.S. Patent Documents. *Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.